IL140822A0 - Oxazolo, thiazolo and selenazolo (4,5-c) quinolin-4-amines and analogs thereof - Google Patents

Oxazolo, thiazolo and selenazolo (4,5-c) quinolin-4-amines and analogs thereof

Info

Publication number
IL140822A0
IL140822A0 IL14082299A IL14082299A IL140822A0 IL 140822 A0 IL140822 A0 IL 140822A0 IL 14082299 A IL14082299 A IL 14082299A IL 14082299 A IL14082299 A IL 14082299A IL 140822 A0 IL140822 A0 IL 140822A0
Authority
IL
Israel
Prior art keywords
selenazolo
oxazolo
thiazolo
quinolin
analogs
Prior art date
Application number
IL14082299A
Other languages
English (en)
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of IL140822A0 publication Critical patent/IL140822A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
    • C07D517/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
IL14082299A 1998-07-28 1999-07-28 Oxazolo, thiazolo and selenazolo (4,5-c) quinolin-4-amines and analogs thereof IL140822A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9434698P 1998-07-28 1998-07-28
US09/361,544 US6110929A (en) 1998-07-28 1999-07-27 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
PCT/US1999/017027 WO2000006577A1 (en) 1998-07-28 1999-07-28 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF

Publications (1)

Publication Number Publication Date
IL140822A0 true IL140822A0 (en) 2002-02-10

Family

ID=26788753

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14082299A IL140822A0 (en) 1998-07-28 1999-07-28 Oxazolo, thiazolo and selenazolo (4,5-c) quinolin-4-amines and analogs thereof

Country Status (25)

Country Link
US (9) US6110929A (pt)
EP (1) EP1100802B1 (pt)
JP (1) JP4662630B2 (pt)
KR (1) KR100696349B1 (pt)
CN (1) CN1147493C (pt)
AT (2) ATE320435T1 (pt)
AU (1) AU748050B2 (pt)
BR (1) BR9912448A (pt)
CA (1) CA2338504C (pt)
CZ (1) CZ291753B6 (pt)
DE (2) DE69911622T2 (pt)
DK (1) DK1100802T3 (pt)
ES (2) ES2203160T3 (pt)
HK (1) HK1038228A1 (pt)
HU (1) HUP0103137A3 (pt)
IL (1) IL140822A0 (pt)
MX (1) MXPA01000757A (pt)
NO (1) NO20010497L (pt)
NZ (1) NZ509420A (pt)
PL (1) PL347590A1 (pt)
PT (2) PT1380587E (pt)
RU (1) RU2244717C2 (pt)
SK (1) SK1402001A3 (pt)
TR (1) TR200100278T2 (pt)
WO (1) WO2000006577A1 (pt)

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
ATE304852T1 (de) 1999-01-08 2005-10-15 3M Innovative Properties Co Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
EP1360486A2 (en) * 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
AU2006216669A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
EP1427445A4 (en) * 2001-08-30 2006-09-06 3M Innovative Properties Co METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES
JP2005519990A (ja) * 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
PT1719511E (pt) * 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ATE373503T1 (de) * 2002-02-06 2007-10-15 Ares Trading Sa Tumornekrosefaktor in kombination mit interferon in demyelinierungskrankheiten
CA2475595C (en) * 2002-02-22 2012-07-10 3M Innovative Properties Company Method of reducing and preventing uvb-induced immunosuppression
ATE491471T1 (de) * 2002-03-19 2011-01-15 Powderject Res Ltd Adjuvantien für dns impstoffe basierend auf imidazochinoline
WO2003080112A2 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
IL164354A0 (en) 2002-04-04 2005-12-18 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
NZ537054A (en) * 2002-06-07 2006-10-27 3M Innovative Properties Co Ether substituted imidazopyridines
EP2269632B1 (en) 2002-08-15 2014-01-01 3M Innovative Properties Co. Immunostimulatory compositions and methods of stimulating an immune response
AU2003299082A1 (en) * 2002-09-26 2004-04-19 3M Innovative Properties Company 1h-imidazo dimers
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
WO2004080398A2 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
JP2006520245A (ja) 2003-03-13 2006-09-07 スリーエム イノベイティブ プロパティズ カンパニー 入れ墨の除去方法
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF IMMUNE-RESPONSE-MODIFYING COMPOUNDS USING PARTICULATE CARRIER MATERIALS CONTAINING METAL
US20040214851A1 (en) * 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
AR044466A1 (es) * 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
KR20060054371A (ko) * 2003-07-31 2006-05-22 쓰리엠 이노베이티브 프로퍼티즈 컴파니 캡슐화 및 제어된 방출을 위한 조성물
JP2007501252A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
BRPI0412902A (pt) * 2003-08-12 2006-09-26 3M Innovative Properties Co compostos contendo imidazo substituìdo por oxima
CA2535338C (en) * 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
CA2536578A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
WO2005029037A2 (en) * 2003-09-17 2005-03-31 3M Innovative Properties Company Selective modulation of tlr gene expression
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
RU2412942C2 (ru) 2003-10-03 2011-02-27 3М Инновейтив Пропертиз Компани Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
JP2007508305A (ja) 2003-10-03 2007-04-05 スリーエム イノベイティブ プロパティズ カンパニー ピラゾロピリジンおよびその類似物
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
AU2004291101A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
MY161812A (en) 2003-11-25 2017-05-15 3M Innovative Properties Co Substituted imidazo ring systems and methods
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
CN1914203A (zh) * 2003-12-04 2007-02-14 3M创新有限公司 砜取代的咪唑环醚
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312510A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
CA2559607C (en) * 2004-03-15 2013-02-19 3M Innovative Properties Company Immune response modifier formulations and methods
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
US20060051374A1 (en) * 2004-04-28 2006-03-09 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20070259907A1 (en) * 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co HIV IMMUNOSTIMATORY COMPOSITIONS
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
CA2578741C (en) * 2004-09-02 2014-01-14 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2006031878A2 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
US7557211B2 (en) * 2004-11-12 2009-07-07 Bristol-Myers Squibb Company 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
ES2377758T3 (es) 2004-11-12 2012-03-30 Bristol-Myers Squibb Company Compuestos tricíclicos basados en tiazolo[4,5-b]piridina imidazo-fusionada y composiciones farmacéuticas que los comprenden
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
JP2008526765A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1830880A4 (en) * 2004-12-30 2008-03-26 Coley Pharm Group Inc MULTI-CHANNEL ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
NZ556399A (en) * 2004-12-30 2009-03-31 Takeda Pharmaceutical 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
AU2006212765B2 (en) * 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
CA2598437A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
WO2006099275A2 (en) 2005-03-14 2006-09-21 3M Innovative Properties Company Method of treating actinic keratosis
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1874345B1 (en) * 2005-04-25 2012-08-15 3M Innovative Properties Company Immunostimulatory compositions
US20100017895A1 (en) 2005-07-18 2010-01-21 Amy Weiner Small animal model for hcv replication
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US8258191B2 (en) * 2005-10-31 2012-09-04 Coloplast A/S Topical skin barriers and methods of evaluation thereof
CA2628131C (en) 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PT2478916T (pt) 2006-01-27 2020-07-03 Seqirus Uk Ltd Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008010963A2 (en) * 2006-07-18 2008-01-24 3M Innovative Properties Company Immune response modifier formulations
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8124096B2 (en) * 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
PL2061765T3 (pl) 2006-09-01 2015-04-30 Senhwa Biosciences Inc Modulatory białkowych kinaz serynowo-treoninowych i PARP
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
CN101568351B (zh) * 2006-12-22 2012-05-30 3M创新有限公司 控制释放的组合物和方法
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2217236A1 (en) * 2007-11-02 2010-08-18 Yaupon Therapeutics, Inc. Use of lobeline epimers in the treatment of central nervous system diseases, pathologies, and drug abuse
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
KR20100135766A (ko) 2008-03-18 2010-12-27 노파르티스 아게 인플루엔자 바이러스 백신 항원 제조의 개선
PT2382474E (pt) 2009-01-20 2015-06-03 Transgene Sa Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
MX2011010061A (es) 2009-03-24 2011-11-18 Transgene Sa Biomarcador para monitorear pacientes.
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
MX2011010920A (es) 2009-04-17 2011-11-04 Transgene Sa Biomarcador para monitorear pacientes.
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
NZ596325A (en) 2009-07-10 2013-11-29 Transgene Sa Biomarker for selecting patients and related methods
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
EP4159232A1 (en) 2011-01-26 2023-04-05 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
ES2691745T3 (es) 2011-04-08 2018-11-28 Janssen Sciences Ireland Uc Derivados de pirimidina para el tratamiento de infecciones víricas
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
MX347240B (es) 2011-06-03 2017-04-20 3M Innovative Properties Co Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
PE20141359A1 (es) * 2011-10-21 2014-10-13 Glaxosmithkline Llc Compuestos y metodos para mejorar las respuestas inmunitarias innatas
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
US9556176B2 (en) 2011-11-09 2017-01-31 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
KR20200075023A (ko) 2012-05-04 2020-06-25 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
KR102207888B1 (ko) 2012-07-13 2021-01-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염증의 치료를 위한 거대환식 푸린
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2013301450B2 (en) 2012-08-10 2018-01-18 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
SG11201502622VA (en) 2012-10-10 2015-05-28 Janssen Sciences Ireland Uc PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
HUE051988T2 (hu) 2013-01-07 2021-04-28 Univ Pennsylvania Készítmények és eljárások bõr T-sejt lymphoma kezelésére
US9598378B2 (en) 2013-02-21 2017-03-21 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
US9072747B2 (en) 2013-03-10 2015-07-07 Peritech Pharma Ltd. Topical compositions and methods of treatment of anorectal disorders
EA202090547A3 (ru) 2013-03-29 2020-12-30 Янссен Сайенсиз Айрлэнд Юси Макроциклические деаза-оксипурины для лечения вирусных инфекций
MY188071A (en) 2013-05-24 2021-11-16 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
EP3024476A1 (en) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
SG11201510736PA (en) 2013-07-30 2016-02-26 Janssen Sciences Ireland Uc THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
AU2014347059B2 (en) 2013-11-05 2017-09-07 Solventum Intellectual Properties Company Sesame oil based injection formulations
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
CN114716555A (zh) 2014-01-10 2022-07-08 博笛生物科技有限公司 靶向表达egfr的肿瘤的化合物和组合物
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
SI3122378T1 (sl) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
WO2015193506A1 (en) 2014-06-20 2015-12-23 Institut Pasteur Korea Anti-infective compounds
AU2015286043B2 (en) 2014-07-09 2020-08-20 Birdie Biopharmaceuticals Inc. Anti-PD-L1 combinations for treating tumors
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016180274A1 (zh) * 2015-05-09 2016-11-17 江苏新元素医药科技有限公司 用于治疗或预防乳腺癌的化合物
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
MX2018002017A (es) 2015-08-31 2018-03-26 3M Innovative Properties Co Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
EP3344623B1 (en) 2015-08-31 2021-02-17 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing substituted guanidine groups
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
AU2016343682A1 (en) 2015-10-30 2018-06-14 The Regents Of The University Of California Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
IL299285A (en) 2016-05-16 2023-02-01 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
IL313085A (en) 2016-05-16 2024-07-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
JP7171444B2 (ja) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染治療用のジヒドロピラノピリミジン
EP3504215B1 (en) 2016-08-26 2022-04-06 3M Innovative Properties Company Fused [1,2]imidazo[4,5-c]ring compounds substituted with guanidino groups
CA3033542A1 (en) 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity
KR102450287B1 (ko) 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018160552A1 (en) 2017-03-01 2018-09-07 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
MX2019015744A (es) 2017-06-23 2020-02-20 Birdie Biopharmaceuticals Inc Composiciones farmaceuticas.
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
WO2019099412A1 (en) 2017-11-14 2019-05-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN111788202B (zh) 2018-02-28 2024-03-01 3M创新有限公司 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
BR112020016859A2 (pt) 2018-02-28 2020-12-29 Pfizer Inc. Variantes de il-15 e usos da mesma
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CA3097865A1 (en) 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
BR112020022897A2 (pt) 2018-05-23 2021-02-23 Pfizer Inc. anticorpos específicos para cd3 e usos dos mesmos
BR112020022595A2 (pt) 2018-05-23 2021-02-09 Pfizer Inc. anticorpos específicos para gucy2c e usos dos mesmos
US11884662B2 (en) 2018-05-24 2024-01-30 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
EP3887369B1 (en) 2018-11-26 2024-05-08 Solventum Intellectual Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
EP3980415A1 (en) 2019-06-06 2022-04-13 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
CN113906027A (zh) 2019-06-12 2022-01-07 3M创新有限公司 具有N-1支链基团的苯乙基取代的咪唑并[4,5-c]喹啉化合物
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
EP4077387A1 (en) 2019-12-17 2022-10-26 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
JP2023533011A (ja) 2020-07-08 2023-08-01 スリーエム イノベイティブ プロパティズ カンパニー Ｎ－１分岐イミダゾキノリン、そのコンジュゲート、及び方法
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
WO2022130046A1 (en) 2020-12-16 2022-06-23 3M Innovative Properties Company N-1 branched imidazoquinolines, conjugates thereof, and methods
WO2023111726A1 (en) 2021-12-14 2023-06-22 3M Innovative Properties Company N-1 triazole substituted imidazoquinolines, conjugates thereof, and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2288521A1 (fr) * 1974-10-25 1976-05-21 Merck Patent Gmbh Nouvelles penicillines et procede pour leur preparation
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
US4131677A (en) * 1975-05-02 1978-12-26 Merck & Co., Inc. Anti-inflammatory oxazolo [5,4-b]pyridines
US4275065A (en) * 1979-06-21 1981-06-23 American Home Products Corporation Modulating the immune response with 2-substituted-3-hydroxythiazolo[2,3-b]be
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
HU197019B (en) * 1985-11-12 1989-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing thiqzolo (4,5-c) quinoline derivatives and pharmaceuticals comprising same
HU196308B (en) * 1985-11-12 1988-11-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions containing 2-methyl-thiazolo/4,5-c/quinoline as active component
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US5266376A (en) * 1989-12-25 1993-11-30 Toray Industries, Inc. Magnetic recording medium
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CZ288182B6 (en) * 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
WO1998016514A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
FR2761071B1 (fr) * 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
ATE304852T1 (de) * 1999-01-08 2005-10-15 3M Innovative Properties Co Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Also Published As

Publication number Publication date
KR20010085309A (ko) 2001-09-07
US20040122041A1 (en) 2004-06-24
US6110929A (en) 2000-08-29
US6323200B1 (en) 2001-11-27
PL347590A1 (en) 2002-04-08
CN1320126A (zh) 2001-10-31
US20030064968A1 (en) 2003-04-03
WO2000006577A1 (en) 2000-02-10
US20030195224A1 (en) 2003-10-16
US6809203B2 (en) 2004-10-26
JP4662630B2 (ja) 2011-03-30
ES2260554T3 (es) 2006-11-01
PT1100802E (pt) 2004-02-27
EP1100802A1 (en) 2001-05-23
DK1100802T3 (da) 2004-02-09
DE69930327T2 (de) 2006-12-07
TR200100278T2 (tr) 2001-08-21
HK1038228A1 (en) 2002-03-08
US6677334B2 (en) 2004-01-13
US7148232B2 (en) 2006-12-12
US6703402B2 (en) 2004-03-09
US6627638B2 (en) 2003-09-30
US20020072528A1 (en) 2002-06-13
SK1402001A3 (en) 2001-08-06
HUP0103137A3 (en) 2002-06-28
RU2244717C2 (ru) 2005-01-20
US20050026943A1 (en) 2005-02-03
NO20010497D0 (no) 2001-01-29
DE69911622D1 (de) 2003-10-30
NZ509420A (en) 2003-08-29
DE69911622T2 (de) 2004-06-17
NO20010497L (no) 2001-03-27
HUP0103137A2 (hu) 2002-01-28
CA2338504C (en) 2011-03-08
KR100696349B1 (ko) 2007-03-20
ATE320435T1 (de) 2006-04-15
ATE250612T1 (de) 2003-10-15
CZ291753B6 (cs) 2003-05-14
US20030065006A1 (en) 2003-04-03
DE69930327D1 (de) 2006-05-11
PT1380587E (pt) 2006-08-31
EP1100802B1 (en) 2003-09-24
JP2002524392A (ja) 2002-08-06
AU5133199A (en) 2000-02-21
BR9912448A (pt) 2001-10-09
ES2203160T3 (es) 2004-04-01
US20030045545A1 (en) 2003-03-06
CN1147493C (zh) 2004-04-28
CA2338504A1 (en) 2000-02-10
US6627640B2 (en) 2003-09-30
CZ2001327A3 (cs) 2001-08-15
MXPA01000757A (es) 2002-04-08
US6440992B1 (en) 2002-08-27
AU748050B2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
IL140822A0 (en) Oxazolo, thiazolo and selenazolo (4,5-c) quinolin-4-amines and analogs thereof
NZ212632A (en) Tumor necrosis factor, its preparation and its use
IL136556A0 (en) Imidazonaphthyridines and their use in inducing cytokine biosynthesis
CA2290520A1 (en) Inhibition of p38 kinase activity by aryl ureas
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
IL114003A (en) 1,4,6-Trisubstituted 1H-pyrrolo[2,3-b]pyridine and 1-H-pyrazolo[3,4-b] pyridine derivatives and pharmaceutical compositions containing them and some intermediates for their preparation
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
IL150984A0 (en) Modified cytokines for use in cancer therapy
EP0204989A3 (en) Use of penicillamine in the treatment of immune deficiency diseases
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
WO2003022225A3 (en) Compositions comprising mixtures of therapeutic proteins and methods of producing the same
BG104368A (en) Novel polymorphic forms of cipamfylline
AU2002349013A1 (en) Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.